A Phase Ib/II, Multicenter Study of GT90001 in Combination With KN046 in Patients With Advanced or Refractory Solid Tumors
Latest Information Update: 14 Feb 2024
At a glance
- Drugs Erfonrilimab (Primary) ; GT 90001 (Primary)
- Indications Adenocarcinoma; Bladder cancer; Carcinoma; Gastric cancer; Liver cancer; Oesophageal cancer; Renal cancer; Solid tumours; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Suzhou Kintor Pharmaceuticals
- 08 Feb 2024 Planned End Date changed from 1 Sep 2025 to 1 Dec 2025.
- 08 Feb 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Apr 2025.
- 02 Nov 2021 According to a Kintor Pharmaceutical Limited media release, first patient has been enrolled and dosed in Taiwan, China.